Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 15 | 2023 | 1017 | 3.830 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2019 | 126 | 2.910 |
Why?
|
| Dyslipidemias | 5 | 2023 | 52 | 2.280 |
Why?
|
| Practice Guidelines as Topic | 10 | 2018 | 375 | 1.950 |
Why?
|
| Troponin T | 4 | 2019 | 59 | 1.850 |
Why?
|
| Risk Assessment | 12 | 2019 | 1312 | 1.790 |
Why?
|
| Heart Failure | 6 | 2017 | 571 | 1.770 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2019 | 9 | 1.730 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 369 | 1.510 |
Why?
|
| Hypertension | 7 | 2023 | 912 | 1.400 |
Why?
|
| Myocardial Infarction | 7 | 2017 | 413 | 1.340 |
Why?
|
| Cardiology | 4 | 2017 | 72 | 1.330 |
Why?
|
| United States | 24 | 2023 | 3648 | 1.290 |
Why?
|
| Cholesterol, LDL | 3 | 2019 | 157 | 1.280 |
Why?
|
| American Heart Association | 4 | 2017 | 84 | 1.260 |
Why?
|
| Guideline Adherence | 7 | 2018 | 111 | 1.260 |
Why?
|
| Hospitalization | 4 | 2017 | 417 | 1.230 |
Why?
|
| Atherosclerosis | 6 | 2022 | 698 | 1.230 |
Why?
|
| Registries | 10 | 2019 | 280 | 1.210 |
Why?
|
| Football | 4 | 2014 | 73 | 1.170 |
Why?
|
| Male | 40 | 2023 | 17872 | 1.130 |
Why?
|
| Middle Aged | 30 | 2020 | 10868 | 1.120 |
Why?
|
| Retirement | 3 | 2014 | 11 | 1.120 |
Why?
|
| Humans | 50 | 2023 | 29213 | 1.060 |
Why?
|
| Cognition | 2 | 2019 | 526 | 1.040 |
Why?
|
| Female | 36 | 2023 | 18236 | 1.000 |
Why?
|
| Stroke Volume | 2 | 2017 | 280 | 0.980 |
Why?
|
| Risk Factors | 21 | 2019 | 3547 | 0.970 |
Why?
|
| Carotid Artery Diseases | 2 | 2014 | 109 | 0.910 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 360 | 0.910 |
Why?
|
| Lipoprotein(a) | 2 | 2019 | 10 | 0.850 |
Why?
|
| Intermittent Claudication | 2 | 2018 | 9 | 0.820 |
Why?
|
| Health Status | 4 | 2017 | 369 | 0.810 |
Why?
|
| Coronary Disease | 3 | 2016 | 200 | 0.780 |
Why?
|
| Cholesterol | 3 | 2017 | 229 | 0.780 |
Why?
|
| Aged | 22 | 2019 | 9510 | 0.750 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 232 | 0.750 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 57 | 0.700 |
Why?
|
| Apolipoproteins B | 1 | 2019 | 44 | 0.690 |
Why?
|
| Obesity | 4 | 2023 | 1068 | 0.680 |
Why?
|
| Cognition Disorders | 2 | 2019 | 390 | 0.670 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2016 | 13 | 0.660 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 18 | 0.650 |
Why?
|
| Time Factors | 13 | 2019 | 2003 | 0.630 |
Why?
|
| Adult | 16 | 2023 | 8466 | 0.600 |
Why?
|
| Hospital Costs | 1 | 2017 | 36 | 0.600 |
Why?
|
| Health Status Disparities | 1 | 2018 | 114 | 0.590 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 101 | 0.590 |
Why?
|
| Mortality | 1 | 2017 | 109 | 0.590 |
Why?
|
| Triglycerides | 1 | 2017 | 214 | 0.580 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 12 | 0.580 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 55 | 0.580 |
Why?
|
| Forecasting | 1 | 2017 | 133 | 0.580 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 49 | 0.570 |
Why?
|
| Blood Pressure | 5 | 2020 | 807 | 0.570 |
Why?
|
| Peptide Fragments | 1 | 2019 | 422 | 0.560 |
Why?
|
| Inservice Training | 1 | 2016 | 11 | 0.560 |
Why?
|
| Body Mass Index | 3 | 2019 | 867 | 0.560 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 49 | 0.550 |
Why?
|
| Prospective Studies | 9 | 2019 | 2027 | 0.550 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 65 | 0.540 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 45 | 0.540 |
Why?
|
| Exercise Therapy | 1 | 2018 | 229 | 0.540 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 3 | 0.540 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 327 | 0.540 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 14 | 0.530 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.530 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 59 | 0.530 |
Why?
|
| Diabetes Complications | 1 | 2016 | 171 | 0.530 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 175 | 0.520 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 116 | 0.510 |
Why?
|
| Waist Circumference | 1 | 2014 | 89 | 0.500 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 195 | 0.500 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 162 | 0.490 |
Why?
|
| Comorbidity | 7 | 2017 | 546 | 0.490 |
Why?
|
| Occupations | 1 | 2014 | 10 | 0.490 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 163 | 0.490 |
Why?
|
| Neck | 1 | 2014 | 26 | 0.480 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 153 | 0.480 |
Why?
|
| Athletes | 1 | 2014 | 65 | 0.480 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2019 | 82 | 0.470 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1131 | 0.460 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3108 | 0.430 |
Why?
|
| Incidence | 5 | 2019 | 1123 | 0.420 |
Why?
|
| African Americans | 1 | 2018 | 1373 | 0.380 |
Why?
|
| Lipids | 3 | 2017 | 211 | 0.370 |
Why?
|
| Prognosis | 4 | 2017 | 1363 | 0.370 |
Why?
|
| Cohort Studies | 5 | 2017 | 1694 | 0.370 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 16 | 0.360 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2114 | 0.350 |
Why?
|
| Calcinosis | 3 | 2014 | 143 | 0.350 |
Why?
|
| Calcium | 3 | 2014 | 297 | 0.330 |
Why?
|
| Stents | 3 | 2017 | 171 | 0.330 |
Why?
|
| Logistic Models | 6 | 2017 | 729 | 0.330 |
Why?
|
| Linear Models | 4 | 2017 | 427 | 0.320 |
Why?
|
| Prevalence | 6 | 2017 | 907 | 0.320 |
Why?
|
| Quality of Life | 3 | 2018 | 819 | 0.320 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 709 | 0.300 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 788 | 0.290 |
Why?
|
| Postprandial Period | 2 | 2016 | 10 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 231 | 0.280 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 293 | 0.270 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 104 | 0.270 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 52 | 0.270 |
Why?
|
| Coronary Angiography | 3 | 2017 | 136 | 0.270 |
Why?
|
| Metals | 2 | 2017 | 16 | 0.250 |
Why?
|
| Southeastern United States | 1 | 2023 | 71 | 0.240 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 638 | 0.230 |
Why?
|
| Family Practice | 1 | 2023 | 47 | 0.230 |
Why?
|
| Coronary Vessels | 2 | 2014 | 147 | 0.230 |
Why?
|
| Self Efficacy | 1 | 2023 | 70 | 0.230 |
Why?
|
| Medical History Taking | 1 | 2022 | 32 | 0.220 |
Why?
|
| Refugees | 1 | 2022 | 5 | 0.210 |
Why?
|
| India | 3 | 2016 | 61 | 0.210 |
Why?
|
| Odds Ratio | 4 | 2016 | 448 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2019 | 91 | 0.200 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 3726 | 0.200 |
Why?
|
| North Carolina | 2 | 2023 | 1424 | 0.190 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 379 | 0.190 |
Why?
|
| Health Facilities | 1 | 2020 | 11 | 0.190 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 30 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2017 | 183 | 0.180 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 29 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2019 | 22 | 0.180 |
Why?
|
| Models, Statistical | 2 | 2017 | 164 | 0.170 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 17 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 35 | 0.170 |
Why?
|
| Emigration and Immigration | 1 | 2019 | 32 | 0.170 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 58 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 271 | 0.170 |
Why?
|
| Thinness | 1 | 2019 | 31 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 1365 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 864 | 0.170 |
Why?
|
| Secondary Prevention | 1 | 2019 | 59 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 273 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2019 | 94 | 0.160 |
Why?
|
| Canada | 1 | 2018 | 49 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 533 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 165 | 0.150 |
Why?
|
| Coronary Restenosis | 2 | 2017 | 13 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 110 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2018 | 190 | 0.150 |
Why?
|
| Cause of Death | 1 | 2017 | 220 | 0.150 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 36 | 0.150 |
Why?
|
| Patient Preference | 1 | 2017 | 38 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2016 | 47 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 114 | 0.140 |
Why?
|
| Heterozygote | 1 | 2016 | 52 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 48 | 0.140 |
Why?
|
| Texas | 1 | 2016 | 35 | 0.140 |
Why?
|
| Veterans | 1 | 2016 | 50 | 0.140 |
Why?
|
| Transients and Migrants | 1 | 2019 | 281 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 59 | 0.140 |
Why?
|
| Double-Blind Method | 1 | 2017 | 504 | 0.140 |
Why?
|
| Developing Countries | 1 | 2016 | 43 | 0.140 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 68 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3121 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 724 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 19 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 134 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 641 | 0.130 |
Why?
|
| Monocytes | 1 | 2016 | 119 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2016 | 97 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2016 | 267 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2015 | 122 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2016 | 136 | 0.130 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 50 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2015 | 90 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2015 | 149 | 0.130 |
Why?
|
| Alleles | 1 | 2015 | 251 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 466 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2016 | 333 | 0.130 |
Why?
|
| Survival Rate | 1 | 2016 | 795 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 18 | 0.120 |
Why?
|
| Anthropometry | 1 | 2014 | 82 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2016 | 181 | 0.120 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 56 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 343 | 0.120 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 33 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1382 | 0.110 |
Why?
|
| Apoptosis | 1 | 2015 | 337 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2016 | 307 | 0.110 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 15 | 0.110 |
Why?
|
| Mutation | 1 | 2015 | 466 | 0.110 |
Why?
|
| Young Adult | 2 | 2017 | 2413 | 0.110 |
Why?
|
| Mass Screening | 1 | 2014 | 225 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 314 | 0.100 |
Why?
|
| Smoking | 1 | 2014 | 439 | 0.100 |
Why?
|
| Inflammation | 1 | 2014 | 508 | 0.100 |
Why?
|
| Nepal | 2 | 2020 | 9 | 0.090 |
Why?
|
| Thrombosis | 1 | 2011 | 60 | 0.090 |
Why?
|
| Stroke | 1 | 2015 | 549 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2017 | 87 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 9 | 0.060 |
Why?
|
| Bhutan | 1 | 2022 | 1 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 3265 | 0.050 |
Why?
|
| Focus Groups | 1 | 2022 | 104 | 0.050 |
Why?
|
| Public Sector | 1 | 2020 | 2 | 0.050 |
Why?
|
| Private Sector | 1 | 2020 | 8 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2020 | 8 | 0.050 |
Why?
|
| World Health Organization | 1 | 2020 | 15 | 0.050 |
Why?
|
| Health Resources | 1 | 2020 | 33 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 144 | 0.050 |
Why?
|
| Urban Population | 1 | 2020 | 79 | 0.050 |
Why?
|
| Health Surveys | 1 | 2020 | 191 | 0.050 |
Why?
|
| Sweden | 1 | 2019 | 14 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 5 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 17 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2019 | 42 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 19 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 64 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 21 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 66 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 248 | 0.040 |
Why?
|
| Spain | 1 | 2017 | 3 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2019 | 188 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 54 | 0.040 |
Why?
|
| Missouri | 1 | 2017 | 12 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 40 | 0.040 |
Why?
|
| Drug Costs | 1 | 2017 | 42 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 572 | 0.040 |
Why?
|
| Patient Participation | 1 | 2017 | 62 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2016 | 61 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 181 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 116 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 257 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 122 | 0.030 |
Why?
|
| Outpatients | 1 | 2015 | 49 | 0.030 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 29 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 208 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 40 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 40 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 96 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 89 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 629 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 478 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2012 | 10 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2012 | 17 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 519 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1110 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 242 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 141 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 67 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 836 | 0.030 |
Why?
|
| Propensity Score | 1 | 2011 | 34 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 35 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 50 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 235 | 0.020 |
Why?
|